Skin testing and hypersensitivity reactions to oxaliplatin

Garufi, Carlo; Cristaudo, Antonio; Vanni, Barbara; Bria, Emilio; Aschelter, A.; Santucci, B.; Terzoli, E.

doi:10.1093/annonc/mdg092

Cited by 57 publications

(44 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, there is not perfect tool to predict oxaliplatin-related hypersensitivity reactions. Skin testing for oxaliplatin showed 75% to 80% accuracy in previous two studies (Garufi et al, 2003;Morgan et al, 1994), but the usefulness of skin testing remains an issue of controversy (Makrilia et al, 2010).…”

Section: Discussionmentioning

confidence: 98%

Hypersensitivity Reactions to Oxaliplatin: Clinical Features and Risk Factors in Koreans

Kim¹,

Kang²,

Lee³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Hypersensitivity Reactions to Oxaliplatin: Clinical Features and Risk Factors in Koreans

Kim¹,

Kang²,

Lee³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…However, no intradermal test is recommended before oxaliplatin administration. An intradermal skin test for hypersensitivity to oxaliplatin has been reported in small series to be 75%-80% accurate [25] . The investigators suggested that desensitization might be considered for patients with a mild to moderate skin reaction in whom oxaliplatin would be beneficial.…”

Section: Discussionmentioning

confidence: 99%

“…Garufi et al reported the skin test to be negative in 15 patients with no previous reactions to oxaliplatin. A positive skin-test reaction is helpful; however, negative results may be seen in some patients who experience hypersensitivity [25] . Two of 8 patients with prior hypersensitivity reactions to oxaliplatin were reported by Meyer et al [7] to have negative skin tests with oxaliplatin, as did 1 of 3 patients described by Thomas et al [5] .…”

Section: Discussionmentioning

confidence: 99%

Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatin-induced hypersensitivity reaction

Saif

Roy²,

Ledbetter³

et al. 2007

WJG

View full text Add to dashboard Cite

Hypersensitivity reactions (HSR) to oxaliplatin in patients with colorectal cancer include facial flushing, erythema, pruritis, fever, tachycardia, dyspnea, tongue swelling, rash/hives, headache, chills, weakness, vomiting, burning sensations, dizziness, and edema. We report a patient with fever as the sole manifestation of initial HSR, review the literature and discuss the management of HSR. A 57-year-old female with T3N2M0 rectal adenocarcinoma received modified FOLFOX-6. She tolerated the first 8 cycles without any toxicities except grade 1 peripheral neuropathy and nausea. During 9 th and 10 th infusions, she developed fever to a maximum of 38.3℃ with stable hemodynamic status despite medications. During 11 th infusion, she developed grade 3 HSR consisting of symptomatic bronchospasm, hypotension, nausea, vomiting, cough, and fever. On examination, she was pale, cyanotic, with a temperature of 38.8℃, BP dropped to 95/43 mm Hg, pulse of 116/min and O2 saturation of 88%-91%. She was hospitalized for management and recovered in 24 h. Fever alone is not a usual symptom of oxaliplatin HSR. It may be indicative that the patient may develop serious reactions subsequently, as did our patient who developed hypotension with the third challenge. Treatment and prevention consists of slowing the infusion rate, use of steroids and antagonists of Type 1 and 2 histamine receptor antagonists, whereas desensitization could help to provide the small number of patients who experience severe HSR with the ability to further receive an effective therapy for their colorectal cancer.

show abstract

“…Successful case reports of desensitization to oxaliplatin have been reported after severe reactions (Gammon, Bhargava, & McCormick, 2004;Meyer, Zuberbier, Worm, Oettle, & Riess, 2002), although some investigators have proposed that patients who develop a severe reaction are unlikely to tolerate additional doses of oxaliplatin (Thomas et al, 2003). Intradermal testing is one method that can be used to predict hypersensitivity reactions with oxaliplatin (Garufi et al, 2003). However, additional studies are needed on the use of desensitization protocols and intradermal skin testing with oxaliplatin.…”

Section: Hypersensitivitymentioning

confidence: 99%

Putting Evidence Into Practice

Muehlbauer

Thorpe²,

Davis³

et al. 2009

Clinical Journal of Oncology Nursing

View full text Add to dashboard Cite

This article will provide an overview of the principal toxicities associated with commonly used chemotherapy treatment regimens for metastatic colorectal cancer (mCRC) and explore the role of the oncology nurse in the management of treatment-associated toxicity. Although patients with mCRC have benefited considerably from recent therapeutic advances, the use of more complex treatment regimens has inevitably resulted in an increase in treatment-related toxicities. This can ultimately lead to dose reductions, delays, or discontinuation of therapy, which may negatively affect efficacy outcomes. Early identification and treatment of toxicities often can allow treatment to continue as planned or at a lower dose, if required. The oncology nurse is ideally positioned to assist with the timely recognition and management of side effects. This allows therapy to be continued on schedule and at the appropriate dose, enabling patients to achieve a better clinical outcome and maintain or improve their quality of life.

show abstract

Skin testing and hypersensitivity reactions to oxaliplatin

Cited by 57 publications

References 7 publications

Hypersensitivity Reactions to Oxaliplatin: Clinical Features and Risk Factors in Koreans

Hypersensitivity Reactions to Oxaliplatin: Clinical Features and Risk Factors in Koreans

Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatin-induced hypersensitivity reaction

Putting Evidence Into Practice

Contact Info

Product

Resources

About